Surrozen, Inc. (SRZN)
25.48
-0.27
(-1.05%)
USD |
NASDAQ |
Oct 23, 16:00
25.40
-0.08
(-0.31%)
After-Hours: 20:00
Surrozen Enterprise Value : 203.77M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 203.77M |
| October 22, 2026 | 206.94M |
| October 21, 2026 | 201.89M |
| October 20, 2026 | 199.77M |
| October 19, 2026 | 184.49M |
| October 16, 2026 | 179.79M |
| October 15, 2026 | 198.95M |
| October 14, 2026 | 183.43M |
| October 13, 2026 | 180.61M |
| October 12, 2026 | 195.31M |
| October 09, 2026 | 253.25M |
| October 08, 2026 | 233.04M |
| October 07, 2026 | 199.83M |
| October 06, 2026 | 214.23M |
| October 05, 2026 | 246.67M |
| October 02, 2026 | 248.90M |
| October 01, 2026 | 256.90M |
| September 30, 2026 | 282.52M |
| September 29, 2026 | 280.17M |
| September 28, 2026 | 252.67M |
| September 25, 2026 | 251.49M |
| September 24, 2026 | 300.15M |
| September 23, 2026 | 94.22M |
| September 22, 2026 | 111.15M |
| September 21, 2026 | 98.57M |
| Date | Value |
|---|---|
| September 18, 2026 | 98.81M |
| September 17, 2026 | 103.39M |
| September 16, 2026 | 103.27M |
| September 15, 2026 | 113.15M |
| September 14, 2026 | 113.97M |
| September 11, 2026 | 127.60M |
| September 10, 2026 | 132.89M |
| September 09, 2026 | 139.71M |
| September 08, 2026 | 147.35M |
| September 04, 2026 | 171.80M |
| September 03, 2026 | 169.21M |
| September 02, 2026 | 169.92M |
| September 01, 2026 | 165.22M |
| August 31, 2026 | 163.10M |
| August 28, 2026 | 167.80M |
| August 27, 2026 | 186.49M |
| August 26, 2026 | 182.96M |
| August 25, 2026 | 178.85M |
| August 24, 2026 | 186.02M |
| August 21, 2026 | 186.26M |
| August 20, 2026 | 180.50M |
| August 19, 2026 | 186.49M |
| August 18, 2026 | 186.37M |
| August 17, 2026 | 183.79M |
| August 14, 2026 | 185.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 32.04M |
| Revenue (Quarterly) | 5.00M |
| Total Expenses (Quarterly) | -27.04M |
| EPS Diluted (Quarterly) | -0.4059 |
| Gross Profit Margin (Quarterly) | 98.98% |
| Earnings Yield | -173.8% |
| Normalized Earnings Yield | -97.41 |